Financial Results : Avalon Pharma posts 42% profit leap in H1 2025 to SAR 44.2M; Q2 at SAR 24.8M

Avalon Pharma posts 42% profit leap in H1 2025 to SAR 44.2M; Q2 at SAR 24.8M

10/08/2025 Argaam Exclusive

View other reports

Middle East Pharmaceutical Industries Co. (Avalon Pharma) generated a net profit of SAR 44.2 million in the first half of 2025, a rise of 42% from SAR 31.2 million in the year-earlier period.



Financials (M)

Item 6m 2024 6m 2025 Change‬
Revenues 176.95 215.02 21.5 %
Gross Income 108.58 133.90 23.3 %
Operating Income 36.82 50.84 38.1 %
Net Income 31.17 44.21 41.8 %
Average Shares 20.00 20.00 -
Earnings Per Share before unusual items (Riyals) 1.56 2.21 41.8 %
EPS (Riyal) 1.56 2.21 41.8 %

The six-month profit was spurred by a 22% rise year-on-year (YoY) in topline to SAR 215.02 million as local and export sales increased by 24% and 4%, respectively.

 

Profit margins across all channels improved, while the ratio of operating expenses/revenue declined, raising the company’s operating margin.



Current Quarter Comparison (M)

Compared With The
Item Q2 2024 Q2 2025 Change‬
Revenues 101.13 117.66 16.3 %
Gross Income 63.28 73.63 16.4 %
Operating Income 24.51 28.44 16.1 %
Net Income 21.81 24.81 13.8 %
Average Shares 20.00 20.00 -
Earnings Per Share before unusual items (Riyal) 1.09 1.24 13.8 %
EPS (Riyal) 1.09 1.24 13.8 %

In Q2 2025, net earnings grew 14% to SAR 24.8 million, from SAR 21.8 million in the year-earlier period as topline saw a rise of 16% YoY to SAR 117.66 million. Local sales and exports improved by 42% and 29% YoY, respectively, along with a 9% YoY increase in the private sector sales.

 

On the other hand, selling, distribution, general and administrative expenses increased as Avalon Pharma continues its growth and development investments.

 

On a quarterly basis, the pharmaceutical producer’s bottom line jumped 27.9% from SAR 19.4 million as revenues grew 21%.

 

Total shareholders’ equity, with no minority interest, came in at SAR 385.17 million as of June 30, 2025, up from SAR 337.15 million a year earlier.

View More Financial Results

 

Kindly, you can view the full report by subscribing to the

The report contains the details of the financial statements, The most important financial indicators, Historical information, Charts, and Forecasts of experts.

Contact Us (+966)-92000-7759

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.